---
title: >-
  Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in
  TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort.
description: >-
  Explore this publication on real-world evidence: Change in Lipids:
  Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a
  Diverse, Large…
date: '2019-01-01'
category: Publications
tags:
  - Approval / Commercialization
  - Care
  - DDW
  - PBC
  - Health System Partner
  - Poster Presentation
  - Hepatology
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/approval-commercialization/change-in-lipids-characteristics-and-response-to/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: change-in-lipids-characteristics-and-response-to
id: 18m1eZ5TJHuJyOL2RldJFG
contentType: article
---

## Challenge

OCA and fenofibrate affect lipid metabolism in PBC, but real-world data on lipid changes—both direction and magnitude—associated with these therapies in a diverse, real-world US population with PBC had not been characterized, creating uncertainty for prescribers and sponsors about metabolic safety.

## Solution

The TARGET-PBC cohort was analyzed to characterize lipid parameter changes associated with OCA and fenofibrate use, with descriptive and comparative analyses across patient subgroups defined by treatment type and baseline lipid status.

## Impact

Providing real-world data on lipid changes associated with OCA and fenofibrate in PBC supports the metabolic safety context for these therapies, informs prescriber guidance, and contributes to the post-authorization safety evidence base for second-line PBC treatments.